Vertex Pharmaceuticals should have big winners with pain drug Journavx and two promising pipeline candidates. Summit ...

Gulf South Angels, a New Orleans-based investment network, is investing in non-opioid pain drug startup South Rampart Pharma, ...

In this first of a three-part video interview series, Jeffrey Casberg, M.S., vice president of clinical pharmacy at IPD Analytics, shared his input on Managed Healthcare Executive’s annual Pharmacy ...

Vertex Pharmaceuticals Incorporated ... of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic ...

Vertex Pharmaceuticals, a biotech giant best known for its cystic fibrosis drugs, took a stumble after missing Q1 2025 ...

Detailed price information for Coca-Cola Company (KO-N) from The Globe and Mail including charting and trades.

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine), an oral NaV1.8 inhibitor, as a treatment for acute pain, representing ...

The PGIM Jennison Growth Fund returned - $10.0%, matching the Russell 1000 Growth Index, which also returned -10.0% in Q1 ...